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CHAPTER I 
 
INTRODUCTION 
 
Incidence, Survival and Treatment of Ewing Sarcoma 
Ewing sarcoma is the second most common malignant bone tumor of childhood. This 
aggressive form of cancer is characterized by a high rate of recurrence and low overall survival. 
The current 10-year event-free survival rate for Ewing sarcoma patients is only 55% (1). The 
prognosis is even worse for patients with high-risk, relapsed, or metastatic disease where overall 
survival is less than 30% (2-6). In addition, recent efforts to improve these survival rates have 
been largely unsuccessful, yielding a modest 8% improvement since 1983 (1). 
 There are approximately 225 new cases of Ewing sarcoma diagnosed in patients under 
the age of 20 each year in North America (1,7,8). The disease is slightly more common in boys 
and is rarely found in people of African descent (8,9). The most common sites of primary Ewing 
sarcoma tumor are the pelvic bones (26% of cases), the long bones of the lower extremities (38% 
of cases), or the chest wall (16% of cases) (8). Approximately 25% of Ewing sarcoma patients 
have metastases in the lungs, bone, bone marrow, or other tissues at time of diagnosis (8). 
The treatment of Ewing sarcoma involves both local and systemic therapy (8). Local 
treatment includes surgery, high-dose radiation therapy, or both (8). In the United States, the 
systemic treatment of Ewing sarcoma involves multidrug chemotherapy consisting of alternating 
cycles of vincristine, doxorubicin, cyclophosphamide, and ifosfamide with etoposide (8). Both 
the local and systemic treatments used in this cancer are highly morbid and cause significant side 
effects including fatigue, hair loss, nausea, vomiting, myelosuppression, cardiotoxicity, 
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nephrotoxicity, and difficult-to-treat second malignancies (6,10,11). Due to the morbid nature of 
the current treatment regimen and the relatively low overall survival rates for Ewing sarcoma 
patients, there is a great need for new therapies for this aggressive cancer. 
 
Cell of Origin and Genetic Profile of Ewing Sarcoma 
Ewing sarcoma was first described by James Ewing in 1921 and is an undifferentiated 
small-round-blue-cell tumor with an unknown cell of origin (12,13). Small-round-blue cells are 
undifferentiated, small cells that characteristically stain blue with hematoxylin and eosin staining 
due to their high nuclear-to-cytoplasmic ratios (8,14). The small-round-blue-cell tumors contain 
few distinguishing characteristics that provide little information regarding their cell of origin (13). 
Although it was originally thought that Ewing sarcoma was derived from primitive neuro-
ectodermal cells, there has since been much debate regarding the cell of origin of Ewing sarcoma. 
Endothelial, mesodermal, epithelial, neural, and mesenchymal cells have all been proposed as 
Ewing sarcoma progenitors (15). Despite this debate, recent research supports the hypothesis that 
mesenchymal stem cells are the most likely cell of origin (15,16). 
Ewing sarcoma is genetically defined by the presence of a balanced chromosomal 
translocation (8). Accordingly, detection of this chromosomal translocation by either 
fluorescence in situ hybridization (FISH) or reverse transcriptase-polymerase chain reaction (RT-
PCR) constitutes a definitive diagnosis of Ewing sarcoma (17,18). All balanced translocations in 
this cancer occur between the EWS RNA-binding protein 1 (EWSR1) gene located on 
chromosome 22 and an ETS family gene located on a distinct chromosome (15). The most 
common translocation, occurring in 85% of Ewing sarcoma tumors, is the reciprocal 
translocation between chromosomes 11 and 22, t(11;22)(q24;q12) (19). The remaining 15% of 
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Ewing sarcoma tumors contain other balanced translocations, all involving EWSR1 located on 
chromosome 22 and either chromosome 21 (10% of tumors), 7, 17 or 2 (all less than 1% of 
tumors) (8). In the majority of these tumors, EWSR1 is fused to genes closely related to FLI1, 
such as ERG (10% of tumors), ETV4, ETV1 or FEV (all less than 1% of tumors) (20).  
The importance of these characteristic translocations is highlighted by the fact that Ewing 
sarcoma has one of the lowest somatic mutation rates of any human cancer (21-24). In addition, 
these tumors have few traditional “actionable” driver mutations, such as kinases (21,25). The 
most frequent mutations are deletions and large-scale chromosome gains or losses, which are not 
traditionally thought of as drug targets (22,26,27). Therefore, the most promising drug target is 
the protein product of the chromosomal translocation (22,28). 
 
Function and Activity of EWS-FLI1 in Ewing Sarcoma 
 The protein product of the t(11;22)(q24;q12) translocation is the novel fusion protein, 
EWS-FLI1. This protein results from the in-frame fusion of the 3' portion of the friend leukemia 
virus integration site 1 (FL1) to the 5' portion of EWSR1 (Figure 1). The reciprocal translocation 
that juxtaposes the 5' portion of FLI1 with the 3' portion of EWSR1 forming the FLI1-EWS 
rearrangement is generally not expressed (8,21). 
 EWS-FLI1 localizes to the nucleus where it functions as a dysregulated oncogenic 
transcription factor (29). The carboxyl-terminal domain of wild-type FLI1 encodes a member of 
the ETS transcription factor family and contains a canonical ETS DNA binding domain that 
binds DNA at the canonical ETS GGAA core sequence (30-35). In the fusion protein, the amino-
terminus of wild-type FLI1 is replaced by the several-times-more-potent amino-terminal 
transcriptional activation domain of EWSR1 (36-38). Conversely, the carboxyl-terminal domain 
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of EWSR1, which contains negative regulatory domains, is lost in the fusion protein resulting in 
constitutive activation of EWS-FLI1 (37,39,40). The resulting constitutively active EWS-FLI1 
transcription factor alters the expression of more than 500 genes (41). 
 
Figure 1. The EWS-FLI1 chromosomal translocation. The t(11;22)(q24;q12) 
translocation causes the fusion of the 3' portion of FLI1 on chromosome 11 to the 5' 
portion of EWSR1 on chromosome 22. This results in production of a novel fusion 
protein, EWS-FLI1, which contains the transcriptional activation domain of EWSR1 and 
the DNA binding domain of FLI1. 
A recent study of EWS-FLI1 elucidated the mechanism by which it functions as an 
aberrant transcription factor and regulates target gene expression (42). To induce target gene 
expression, EWS-FLI1 acts as a pioneer transcription factor to create de novo enhancers that 
activate target gene promoters to induce transcription. To create these de novo enhancers, EWS-
FLI1 binds as multimers to microsatellite regions of the genome containing GGAA repeat 
elements and recruits the p300 transcriptional coactivator. To repress target gene expression, 
EWS-FLI1 displaces wild-type ETS transcription factors by binding enhancers that contain 
canonical ETS binding sites. Because these binding sites do not contain GGAA repeats, 
5 
 
 
EWS-FLI1 cannot bind as a multimer, which prevents adequate recruitment of the p300 
transcriptional coactivator and thereby blocks target gene transcription. 
EWS-FLI1 dysregulates, either directly or indirectly, the expression of more than 500 
genes (41,43,44). Because EWS-FLI1 functions as both a transcriptional activator and repressor, 
the expression of these genes can be positively or negatively regulated (15,42). These genes are 
responsible for oncogenic transformation and progression of Ewing sarcoma (29,32,37,41,45-47). 
EWS-FLI1 suppresses genes that tend to be involved in apoptosis and cell cycle arrest, such as 
IGFBP3, CDKN1C (P57), CDKN1A (P21), and TGFB2 (15). On the other hand, EWS-FLI1 
induces expression of genes involved in proliferation, cell differentiation, and cell survival such 
as IGF1, NKX2-2, TOPK, SOX2, and EZH2 (15). Several of the genes regulated by EWS-FLI1 
have been implicated in the hallmarks of cancer, including EZH2 (replicative immortality), 
MMP (tissue invasion and metastasis), BCL2 and TP53 (evasion of apoptosis), and VEGF 
(angiogenesis) (48-50).  
Finally, multiple independent studies have demonstrated that Ewing sarcoma depends on 
the continued activity of EWS-FLI1 for cell survival. A variety of biochemical methods, 
including antisense DNA, small interfering RNA, and dominant negative expression have all 
demonstrated that blocking EWS-FLI1 activity is incompatible with Ewing sarcoma cell survival 
both in vitro and in vivo (51-55). Accordingly, EWS-FLI1 is considered the master regulator of 
the oncogenic program that defines and sustains these tumors (56,57). 
 
Molecularly Targeted Therapy and EWS-FLI1 
 Molecularly targeted therapy is based on the idea that many tumors are dependent on 
specific oncogenes for survival and that interfering with the activity of these oncogenes will 
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block tumor growth and spread (58,59). This type of therapy differs from traditional 
chemotherapy, which inhibits the growth of all rapidly dividing cells by interfering with events 
essential for cell growth and division such as DNA replication and microtubule assembly (59). 
One of the major advantages of molecularly targeted therapies relative to traditional 
chemotherapy is that they cause less damage to normal tissues and therefore are substantially less 
toxic, particularly when targeting proteins unique to the cancer cell (59). These qualities translate 
to equally effective cancer treatment with reduced undesirable side effects (60). Molecularly 
targeted therapies have demonstrated clinical success and more than 20 of these agents have been 
approved by the FDA (59).  
 EWS-FLI1 is an ideal molecular drug target because it is only expressed in Ewing 
sarcoma cells and absolutely critical for cell survival (28). However, it is a challenging target 
because it is a transcription factor (61,62). Transcription factors are difficult drug targets because 
the interactions critical to their activity are mediated by large surface areas and not deep, 
druggable binding pockets traditionally targeted by small molecules (62). Thus, despite the 
promise of targeting oncogenic transcription factors in cancer, this strategy has proven to be 
difficult (61-63). 
In Ewing sarcoma, numerous studies have sought to circumvent the challenges of 
targeting transcription factors by inhibiting critical EWS-FLI1 target genes rather than 
EWS-FLI1 itself (46). A number of these targets have been identified, including IGF1R, 
NKX2-2, GSTM4, NR0B1, GLI1, PDGFC, and EZH2 (44,56,57,64-69). Some of these targets, 
such as IGF1R, have numerous well-established inhibitors that showed tremendous promise for 
the treatment of Ewing sarcoma (70,71). Unfortunately, this strategy has not translated into 
dramatic improvements in patient survival. 
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Because inhibiting EWS-FLI1 downstream targets has proven largely unsuccessful, an 
alternative approach is to embrace the challenges of transcription-factor drug targeting and 
directly target EWS-FLI1 itself using small molecules. In order to accomplish this, a variety of 
methods have been employed. One approach is to screen libraries of small molecules for their 
ability to reverse expression of a panel of EWS-FLI1 target genes (46,72). Two EWS-FLI1 
modulators that have been identified using this method are cytosine arabinoside and midostaurin 
(73,74). A second approach is to screen libraries of small molecules for their ability to disrupt 
critical EWS-FLI1 interactions (46). This approach has been applied in the form of both surface 
plasmon resonance screening and homogenous proximity assay screening, which identified 
YK-4-279 and Shikonin, respectively (75,76). Despite the promise of these compounds, their 
clinical translation has thus far been unsuccessful as they have either failed in phase II clinical 
trials (cytosine arabinoside), proven not to be specific inhibitors of EWS-FLI1 (Shikonin), or 
proven to be insufficient inhibitors of EWS-FLI1 (YK-4-279) (76-78). 
 
Mithramycin as an Inhibitor of EWS-FLI1 
Several years ago, to address the unmet need for EWS-FLI1 inhibitors, our laboratory 
implemented a high-throughput screen of more than 50,000 compounds to identify small 
molecules that block EWS-FLI1 activity (79). The primary screen utilized a cell-based luciferase 
reporter using the promoter of NR0B1, a well-established downstream target of EWS-FLI1 (65). 
A gene-signature-based secondary screen was used to rank the top compounds identified in the 
primary screen. By utilizing a cell-based approach in the primary screen, we were able to more 
easily interrogate a large library of compounds and, at the same time, confirm the bioavailability 
of the target. In addition, the gene-signature-based secondary screen confirmed the specificity of 
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the lead compounds prior to further development as EWS-FLI1 inhibitors. The lead compound 
from this screen was mithramycin. Mithramycin was shown to suppress well-established EWS-
FLI1 downstream targets both in vitro and in vivo. In addition, mithramycin suppressed the 
growth of Ewing sarcoma xenografts in mice, thus establishing mithramycin as an EWS-FLI1 
inhibitor. 
Mithramycin is a DNA binding compound known to bind GC-rich regions of the genome 
(80). Due to its ability to bind DNA, mithramycin blocks the binding of transcription factors to 
promoter regions containing GC-rich regions. The traditional target of the drug is the 
transcription factor SP1 (81). Accordingly, one mechanism of anti-cancer activity attributed to 
mithramycin is its block of SP1 binding (80). In unpublished data, our laboratory has determined 
that mithramycin also blocks binding of EWS-FLI1 to chromatin, leading to a loss in 
transcription initiation (manuscript in preparation). Therefore, we believe that the anti-cancer 
activity of mithramycin in Ewing sarcoma cells is the result of blocking the transcription of 
EWS-FLI1 target genes that the tumor depends on for cell survival. 
Mithramycin was originally investigated in the clinic for its antitumor properties in the 
1960s. Although mithramycin showed some activity in patients with testicular cancer, it was not 
pursued, likely due to the development of other successful treatment regimens for that cancer 
(82,83). Mithramycin was also used in the treatment of hypercalcemia; however, its use in this 
indication was later replaced by the more efficacious bisphosphonates (84-87). In addition, 
mithramycin was administered to a small number of Ewing sarcoma patients between 1962 and 
1973 (88,89). Two of the five patients treated with mithramycin during this time had excellent 
regressions of their tumors. Of these two patients, one had a complete regression with no clinical 
evidence of tumor more than 7 years after mithramycin treatment (88). Despite these impressive 
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clinical results, further clinical trials of mithramycin for Ewing sarcoma were not conducted at 
that time for reasons that are not clear. 
 
Clinical Translation of Mithramycin 
Due to our study demonstrating that mithramycin is a potent inhibitor of EWS-FLI1 and 
the clinical case reports detailing impressive responses achieved in Ewing sarcoma patients 
treated with mithramycin, we translated mithramycin to a phase I/II clinical trial for Ewing 
sarcoma patients. In this clinical trial, two out of the five enrolled patients with multiply 
recurrent, rapidly progressing incurable Ewing sarcoma had stable disease for more than 40 days 
with intravenous mithramycin treatment. Importantly, mithramycin demonstrated a very clean 
toxicity profile, causing no nausea, vomiting, myelosuppression, nephrotoxicity or cardiotoxicity 
in the patients treated. Unfortunately, nearly every patient treated in this trial experienced 
significant liver toxicity with elevations in liver enzyme levels following drug treatment. This 
liver toxicity necessitated dose reductions that limited maximum patient plasma concentrations 
to approximately 20 nM. This concentration is lower than the 50 nM mithramycin that our 
preclinical models suggest is the minimum concentration necessary to block EWS-FLI1 activity 
in vitro (79). Therefore, we believe that the efficacy of mithramycin in the clinical trial was 
limited by insufficient patient plasma levels. 
From the results of the clinical trial of mithramycin in Ewing sarcoma patients, we 
concluded that in order for mithramycin to be a clinically relevant EWS-FLI1 inhibitor, we 
would need to expand the narrow therapeutic window of the drug. The therapeutic window is 
defined as the concentration range in which a drug achieves efficacy (i.e., therapeutic benefit) 
without toxicity. Accordingly, in the case of mithramycin, the therapeutic window is limited by 
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liver toxicity that develops in patients at doses necessary to achieve efficacy. There are two ways 
to expand the therapeutic window—by increasing potency or decreasing toxicity. Increasing the 
potency of a compound lowers the concentration necessary to achieve efficacy. Decreasing the 
toxicity of a compound increases the concentration necessary for patient toxicity. 
 
Expanding the Therapeutic Window of Mithramycin 
The goal of our research is to either increase the potency or limit the toxicity of 
mithramycin to expand the therapeutic window and make the suppression of EWS-FLI1 
achievable in Ewing sarcoma patients. We believe that the key to this expansion lies in 
increasing both the potency and specificity of mithramycin blockade of EWS-FLI1-driven 
transcription. 
This thesis details two complementary approaches to achieve this goal. The first approach 
seeks to identify a combination therapy that specifically blocks EWS-FLI1 activity at 
bioachievable concentrations of mithramycin by targeting multiple steps in the EWS-FLI1 
transcriptional program. The second approach investigates context-dependent changes in gene 
expression to identify drivers of liver toxicity that, when blocked, protect hepatocytes from 
mithramycin toxicity. Together, these studies will provide needed progress in expanding the 
therapeutic window of mithramycin to enable blockade of EWS-FLI1 in Ewing sarcoma patients.  
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CHAPTER II 
 
EXPANDING THE THERAPEUTIC WINDOW OF MITHRAMYCIN BY INCREASING 
POTENCY USING COMBINATION THERAPY 
 
Introduction 
 In a phase I/II clinical trial of mithramycin for Ewing sarcoma patients, dose-limiting 
liver toxicity limited patient plasma levels to approximately 20 nM. However, our preclinical 
models suggest that a minimum concentration of 50 nM mithramycin is required to block 
EWS-FLI1 activity in Ewing sarcoma cells (79). Therefore, it is likely that mithramycin was not 
active in the clinic because it did not reach high enough concentrations in plasma to suppress 
EWS-FLI1. The goal of the work described in this chapter was to develop a combination therapy 
that inhibits EWS-FLI1 activity at the clinically achievable 20 nM concentration of mithramycin.  
To identify potential combination therapies to augment EWS-FLI1 suppression, our 
laboratory completed a siRNA screen of the entire druggable genome to identify genes that, 
when silenced, sensitize TC32 Ewing sarcoma cells to mithramycin. In this study, siRNA was 
used to silence target gene expression in TC32 cells prior to incubation with either 20 nM 
mithramycin or vehicle control. Those genes that, when silenced, significantly potentiated the 
effect of mithramycin on TC32 cell viability were classified as mithramycin sensitizers. Nine of 
the top 12 mithramycin-sensitizing genes were associated with transcription, including 
transcriptional corepressors, various subunits of RNA Polymerase II (RNAP II), and genes 
associated with assembly of the transcriptional complex. These results suggested that a 
combination therapy targeting transcription would sensitize Ewing sarcoma cells to mithramycin.  
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Eukaryotic transcription is characterized by four main steps: initiation, promoter escape, 
elongation, and termination. In initiation, both specific and general transcription factors bind to 
regulatory regions and cooperate with the Mediator coactivator to recruit RNAP II to the gene 
promoter. The carboxyl-terminal domain of RNAP II is then phosphorylated, allowing it to 
escape from the promoter and begin transcribing DNA into RNA before pausing. After RNAP II 
resumes transcribing, elongation follows and the entirety of the gene is converted to RNA. 
Finally, RNAP II is removed from the DNA, the newly synthesized RNA is released and the 
transcriptional process is terminated (90). 
Based on work in our laboratory, we believe that the therapeutic mechanism of 
mithramycin in Ewing sarcoma cells is derived from blockade of transcription initiation. Using 
ChIP analysis, we have determined that mithramycin blocks EWS-FLI1 binding to regulatory 
regions of target genes (manuscript in preparation). This blockade is believed to inhibit the 
initiation of EWS-FLI1-driven transcription. At high concentrations (50 nM), it is likely that 
mithramycin completely blocks EWS-FLI1-driven transcription initiation. However, at lower 
concentrations (20 nM), i.e., concentrations achievable in patients, it is likely that mithramycin 
only partially blocks EWS-FLI1-driven transcription initiation and that Ewing sarcoma cells are 
able to sufficiently evade this block to productively transcribe target genes and sustain 
proliferation. However, it is possible that targeting the next step in transcription, i.e., promoter 
escape, may rescue this evasion that occurs at 20 nM. In theory, the lower dose of mithramycin 
would provide specificity for the EWS-FLI1 transcriptional program and a general blockade in 
transcription would augment this specificity. In addition, the specificity would be further 
increased if the general blockade in transcription were to favor activated transcription, as occurs 
with promoter escape inhibition.  
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To test this hypothesis, a proof of principle study was conducted in which promoter 
escape was inhibited using PHA-767491, a dual CDK9/CDC7 inhibitor (91,92). CDK9 is a 
cyclin-dependent kinase that is a critical member of the positive transcription elongation factor b 
(P-TEFb), which is responsible for facilitating the transition of RNAP II from promoter escape to 
productive elongation (93,94). Consequently, inhibiting CDK9 blocks promoter escape by 
suppressing the activity of P-TEFb. Importantly, P-TEFb has been shown to primarily function at 
the loci of actively transcribed genes (95). Therefore, in addition to blocking promoter escape, 
inhibiting the activity of P-TEFb using a CDK9 inhibitor may have the added benefit of 
specifically suppressing expression of actively transcribed genes, such as EWS-FLI1 target genes.  
Therefore, the goal of this study was to block EWS-FLI1 activity at a bioachievable 
concentration of mithramycin (20 nM) by combining mithramycin blockade of EWS-FLI1-
driven transcription initiation with PHA-767491 blockade of transcription promoter escape. This 
improved blockade of EWS-FLI1 activity was expected to result in superior suppression of 
EWS-FLI1 targets and improved inhibition of Ewing sarcoma cell growth. Furthermore, it was 
anticipated that these effects would mimic the effects of a higher concentration of mithramycin 
(50 nM) known to inhibit EWS-FLI1 activity. 
 
Results and Discussion  
In order to model the disparity between the concentration of mithramycin achievable in 
patients and the minimum concentration of mithramycin necessary to suppress EWS-FLI1 
activity, TC32 Ewing sarcoma cells were incubated with either 20 nM or 50 nM mithramycin in 
vitro. The effect of drug exposure on proliferation was monitored in real time using time-lapse 
microscopy. In order to model drug clearance, mithramycin was removed from the cell culture 
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medium after 24, 48 or 72 hours of exposure. The effect of continuous exposure of Ewing 
sarcoma cells to mithramycin was also investigated for comparison. 
 
Figure 2. Time course of drug exposure with 50 nM mithramycin. TC32 cells were 
exposed to 50 nM mithramycin for 24 (24 h, green), 48 (48 h, black) or 72 (72 h, gray) 
hours before the drug was removed and replaced by fresh cell culture medium. Cells 
were also incubated with 50 nM mithramycin (Continuous, red) or vehicle control 
(Vehicle, blue) continuously for comparison. Drug exposure began at time 0 and 
confluence of the cell culture plate was measured over time by time-lapse microscopy. 
Data are representative of three independent experiments. Error bars represent standard 
error of the mean. 
Continuous incubation of TC32 cells with 50 nM mithramycin dramatically reduced 
proliferation (Figure 2). Vehicle-incubated cells grew to nearly total confluence by 96 hours. In 
contrast, 50 nM mithramycin blocked proliferation over the entire 206-hour drug exposure 
period as evidenced by an unchanging confluence of approximately 2%. In addition, cells 
incubated with this concentration showed minimal recovery when the drug was removed. 
Removal of mithramycin and replacement with fresh cell culture medium after 24 hours allowed 
TC32 cells to recover, but only to 59% confluence (SEM ± 8). In addition, this recovery required 
more than 180 hours after drug removal. Furthermore, once a threshold time of around 48 hours 
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of exposure occurred, there was no cell recovery even up to 8.5 days later. This result suggests 
that sustained inhibition of EWS-FLI1 beyond 48 hours induces long-lasting anti-proliferative 
effects. 
 
Figure 3. Time course of drug exposure with 20 nM mithramycin. TC32 cells were 
exposed to 20 nM mithramycin for 24 (24 h, green), 48 (48 h, black) or 72 (72 h, gray) 
hours before the drug was removed and replaced by fresh cell culture medium. Cells were 
also incubated with 20 nM mithramycin (Continuous, red) or vehicle control (Vehicle, 
blue) continuously for comparison. Drug exposure began at time 0 and confluence of the 
cell culture plate was measured over time by time-lapse microscopy. Data are 
representative of three independent experiments. Error bars represent standard error of 
the mean. 
The identical experiment was then performed with mithramycin at 20 nM, a 
concentration that is achievable in patients. Similar to the experiment with 50 nM mithramycin, a 
concentration of 20 nM of the drug resulted in markedly suppressed cell proliferation (Figure 3). 
Again, vehicle-incubated cells grew to total confluence by 96 hours. However, continuous 
exposure of TC32 cells to 20 nM mithramycin reduced confluence to 23% (SEM ± 4) after 206 
hours. Unfortunately, although impressive, this represents a confluence approximately 10 times 
that of cells incubated with 50 nM mithramycin continuously. Furthermore, in contrast to 50 nM 
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mithramycin, removal of 20 nM mithramycin resulted in almost immediate recovery of the cells 
even up to 72 hours of exposure, although at the later time points the recovery was delayed. 
These results demonstrate that 20 nM mithramycin is less effective than 50 nM 
mithramycin at causing sustained suppression of Ewing sarcoma cell growth. Consistent with the 
theory that sufficient blockade of EWS-FLI1 activity is necessary to inhibit cell survival and 
proliferation, 20 nM mithramycin appears to induce a static, non-proliferating state in which the 
cells remain viable as demonstrated by their recovery upon drug removal. This suggests that, at 
the concentration achieved in patients, the minimal efficacy of mithramycin is explained by 
ineffective long-term suppression of Ewing sarcoma tumor cell growth. 
 
Figure 4. Effect of mithramycin and PHA-767491 on NR0B1 expression. TC32 cells 
were incubated with the indicated concentration of mithramycin (MMA) or PHA-767491 
(PHA) or the combination of 20 nM mithramycin and 2.5 μM PHA-767491 (Combo) for 
18 hours. Fold change in NR0B1 expression was measured by quantitative RT-PCR and 
normalized to cells incubated with vehicle control (Vehicle). Error bars represent 
standard error of the mean. Data are the average of two replicates from two independent 
experiments. **** = P < 0.0001 
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In order to establish the biochemical basis for the disparity between 50 nM mithramycin 
and 20 nM mithramycin, the effect of mithramycin exposure on expression of NR0B1, a well-
established EWS-FLI1 target gene, was interrogated by quantitative RT-PCR (65). Incubation of 
TC32 cells with 50 nM mithramycin for 18 hours suppressed NR0B1 expression almost 3-fold 
relative to vehicle control (fold change = 0.35, SEM ± 0.03; P < 0.0001) whereas 20 nM 
mithramycin had no effect on NR0B1 expression relative to vehicle control (Figure 4). 
 
Figure 5. Western blot analysis of EWS-FLI1 downstream targets and γH2AX. 
TC32 cells were incubated with the indicated concentration of mithramycin and PHA-
767491 for 18 hours. Protein lysates were collected and subjected to western blot 
analysis. The dose-dependent effect of mithramycin (MMA) and PHA-767491 (PHA) 
exposure on expression of the well-established EWS-FLI1 downstream targets EZH2, 
NR0B1 and ID2 as well as γH2AX was then evaluated. A repeat experiment yielded 
similar results. M = cell culture medium-incubated control; V = vehicle-incubated control 
In order to determine whether this enhanced EWS-FLI1 blockade extends to the protein 
level and other EWS-FLI1 targets, western blot analysis was used to measure protein expression 
of the well-established EWS-FLI1 targets NR0B1, EZH2 and ID2 (65,69,96). Incubation of 
TC32 cells for 18 hours with mithramycin at 100, 50 or 20 nM resulted in dose-dependent 
inhibition of NR0B1 and EZH2 expression (Figure 5). Importantly, 20 nM mithramycin showed 
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no suppression of the EWS-FLI1 targets NR0B1 and EZH2. This suggests that 50 nM 
mithramycin more effectively suppresses EWS-FLI1-driven transcription than 20 nM. 
These results are consistent with the hypothesis that 50 nM mithramycin achieves better 
suppression of EWS-FLI1-driven transcription than 20 nM mithramycin. Therefore, the 
divergent effects of 50 nM and 20 nM mithramycin on Ewing sarcoma cells proliferation is 
likely explained by the discrepancy in EWS-FLI1 blockade. Furthermore, the minimal effect of 
mithramycin in Ewing sarcoma patients was presumably because patient plasma levels of the 
drug were insufficient to robustly block EWS-FLI1 activity. 
The hypothesis that a blockade in promoter escape with the CDK9 inhibitor, 
PHA-767491, would improve the inhibition of EWS-FLI1-driven transcription by 20 nM 
mithramycin leading to a marked increase in suppression of cell proliferation and viability was 
tested next. However, in order to test this hypothesis, the active concentration of PHA-767491 
needed to be determined. TC32 cells were incubated with PHA-767491 at concentrations that 
ranged from 20 μM to approximately 40 nM and it was determined that the most active 
concentration of PHA-767491 was 2.5 μM at 48 hours. Accordingly, cells were once again 
incubated with 50 nM mithramycin as well as 20 nM mithramycin in the presence and absence of 
2.5 μM PHA-767491 and the effect on EWS-FLI1 downstream target expression was measured 
by quantitative RT-PCR (Figure 4). Neither 20 nM mithramycin (fold change = 1.06, SEM ± 
0.05) nor 2.5 μM PHA-767491 (fold change = 1.09, SEM ± 0.07) had an effect on NR0B1 
expression. However, the combination suppressed NR0B1 expression nearly 2-fold (fold 
change = 0.57, SEM ± 0.02; P < 0.0001). 
To show that these results extend to the protein level and other EWS-FLI1 targets, the 
effect of incubation with this combination on the protein expression of the known EWS-FLI1 
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downstream targets NR0B1, EZH2 and ID2 was investigated by western blot analysis (Figure 5) 
Again, 20 nM mithramycin had a marginal effect on the expression of NR0B1 and EZH2 by 
itself. Similarly, 2.5 μM PHA-767491 had little effect on the expression of NR0B1, EZH2 or 
ID2. However, the combination of 2.5 μM PHA-767491 and 20 nM mithramycin resulted in 
marked suppression of all three EWS-FLI1 target genes. In addition, similar inhibition of 
EWS-FLI1 targets was observed when 20 nM mithramycin was combined with the IC50 of 
PHA-767491 (1.8 μM). As with mithramycin alone, the combination of these two compounds 
had no effect on protein levels of EWS-FLI1.  
An interesting observation from this study was that incubation with the combination had 
little effect on integrity of DNA, as measured by γH2AX formation in the western blot analysis 
(Figure 5). Histone H2AX is known to be phosphorylated at serine residue 139 to form γH2AX 
at sites of DNA double-strand breaks, making it indicative of DNA damage (97,98). Although 
100 and 50 nM mithramycin caused induction of γH2AX in a dose-dependent manner, 20 nM 
mithramycin and 2.5 μM PHA-767491, as well as the combination, did not cause any γH2AX 
formation. This suggests that the enhanced effect of the combination on EWS-FLI1 target 
suppression is not the result of non-specific DNA damage. 
These results agree with the hypothesis that partial inhibition of EWS-FLI1-driven 
transcription at initiation (mithramycin) and promoter escape (PHA-767491) results in 
synergistic blockade of EWS-FLI1 activity. Furthermore, the block by the combination therapy 
has the added benefit of being less toxic than high concentration mithramycin, as demonstrated 
by γH2AX formation.  
In order to determine if these results translated to the desired suppression of Ewing 
sarcoma cell viability, TC32 cells were incubated with 20 nM mithramycin both in the presence 
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and absence of 2.5 μM PHA-767491 for 48 hours and the effect on viability was measured 
(Figure 6). Cell viability was reduced to 54% (SEM ± 2) by 20 nM mithramycin and 41% 
(SEM ± 5) by 2.5 μM PHA-767491 relative to vehicle-incubated cells. The combination reduced 
cell viability to 14% (SEM ± 2), which represented a significantly greater effect than either 
compound alone (P < 0.0001 for mithramycin and P = 0.002 for PHA-767491). 
 
Figure 6. Effect of mithramycin and PHA-767491 on Ewing sarcoma cell viability. 
TC32 cells were incubated with 20 nM mithramycin (MMA), 2.5 μM PHA-767491 
(PHA), or the combination (Combo) for 48 hours and viability was determined by the 
MTS assay. Viability was normalized to vehicle-incubated cells. Data are the average of 
four independent experiments. Error bars represent standard error of the mean.               
** = P = 0.002; **** = P < 0.0001 
The results of the viability assay were confirmed by time-lapse microscopy in order to 
gain greater insight into the effect over time and model the effect in patients (Figure 7). Although 
there was some sensitization of TC32 cells exposed to the drug combination after 48 hours, the 
effect of the combination was much more dramatic over time. In order to more closely model the 
cell density in tumors, cells were plated at a higher density than in the previous recovery 
experiments. In this case, vehicle-incubated cells grew to 100% confluence (SEM ± 0.2) by 96 
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hours. Additionally, cells grew more effectively in the presence of 20 nM mithramycin, 
achieving 79% confluence (SEM ± 3) by 96 hours. Similarly, cells incubated with 2.5 μM PHA-
767491 reached 87% confluence (SEM ± 3). In contrast, 96-hour exposure of the cells with the 
combination of 2.5 μM PHA-767491 and 20 nM mithramycin markedly suppressed growth to 
21% confluence (SEM ± 1). 
 
Figure 7. Effect of mithramycin and PHA-767491 on Ewing sarcoma cell 
proliferation. TC32 cells were incubated with vehicle control (Vehicle, blue), 20 nM 
mithramycin (MMA, black), 2.5 μM PHA-767491 (PHA, green), or the combination 
(Combo, red) and proliferation was measured by time-lapse microscopy. Drug exposure 
began at time 0. Data are representative of four independent experiments. Error bars 
represent standard error of the mean. 
To demonstrate that the effect of the combination therapy on proliferation is sustained 
over time, TC32 cells were incubated with 20 nM mithramycin and 2.5 μM PHA-767491 both in 
combination and individually (Figure 8). Again, drug clearance was modeled by removing the 
drug from the cell culture medium after 48 hours of exposure. Cells incubated with vehicle 
control grew to nearly total confluence after 96 hours. In addition, removal of either 20 nM 
mithramycin or 2.5 μM PHA-767491 after 48 hours resulted in almost immediate recovery. In 
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contrast, the combination therapy blocked cell proliferation for more than 8.5 days with just 48 
hours of exposure. This sustained block in proliferation was nearly identical to the block 
observed with 50 nM mithramycin previously (Figure 2). This suggests that, in addition to 
similar inhibition of EWS-FLI1 targets at both the mRNA and protein level, the combination 
therapy has an equivalent effect on Ewing sarcoma cell proliferation relative to 50 nM 
mithramycin. 
 
Figure 8. Ewing sarcoma cell proliferation after mithramycin and PHA-767491 
exposure. TC32 cells were exposed to 20 nM mithramycin (MMA, black), 2.5 μM PHA-
767491 (PHA, green), or the combination (Combo, red) for 48 hours before the drug was 
removed and replaced by fresh cell culture medium. Cells were also incubated with 
vehicle control (Vehicle, blue) continuously for comparison. Drug exposure began at 
time 0 and confluence of the cell culture plate was measured over time by time-lapse 
microscopy. Data are representative of three independent experiments. Error bars 
represent standard error of the mean. 
To determine whether the effects observed with PHA-767491 were the result of 
inhibition of promoter escape via CDK9 or a general effect of transcription inhibition, two 
additional CDK9 inhibitors (SNS-032 & flavopiridol) were investigated (99-101). In addition, 
compounds to interrogate other steps in transcription such as initiation (triptolide) and elongation 
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(SN-38) were evaluated in combination with mithramycin (102-104). Finally, a proteasome 
inhibitor (velcade) was evaluated for synergy because it would be expected to only minimally 
affect transcription (Table 1) (105). 
Table 1. Compounds investigated as mithramycin sensitizers. Known targets of each 
compound are listed in column 2 and the step of transcription inhibited is listed in column 
3. Column 4 lists the IC50 value of each compound in TC32 cells, as determined at 48 
hours using the MTS viability assay. Abbreviations: Topo I (Topoisomerase I), XPB 
(Xeroderma Pigmentosum Type B), CDK (Cyclin-dependent kinase) 
 
In order to compare the synergy between mithramycin and PHA-767491 with this panel 
of compounds, TC32 cells were incubated with 20 nM mithramycin in combination with the 
compounds over a range of concentrations and the effect of drug exposure on cell viability was 
measured at 48 hours. Consistent with the hypothesis, the compounds that redundantly targeted 
transcription initiation (triptolide) or targeted transcription elongation (SN-38) showed only 
marginal synergy with 20 nM mithramycin (Figure 9, A). In addition, the compound that had no 
impact on transcription (velcade) showed the least amount of synergy (Figure 9, A). In contrast, 
all three CDK9 inhibitors (PHA-767491, flavopiridol, SNS-032) considerably sensitized TC32 
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cells to 20 nM mithramycin (Figure 9, B). Importantly, although flavopiridol and SNS-032 
inhibit a variety of CDKs, both have been shown to most potently inhibit CDK9 (100). In 
addition, both flavopiridol and SNS-032 have been evaluated in patients and are well tolerated 
both alone and in combination with other agents (106-110). Therefore, it is likely that this 
combination will be readily translatable to the clinic.  
 
Figure 9. Effect of mithramycin combinations on Ewing sarcoma cell viability.       
A) TC32 cells were incubated with an inhibitor of transcription initiation (triptolide, 
6 nM), transcription elongation (SN-38, 1.8 nM), or the proteasome (velcade, 16 nM) in 
the presence (gray) or absence (black) of 20 nM mithramycin for 48 hours and viability 
was determined by the MTS assay. Viability was normalized to vehicle-incubated cells. 
Data are the average of two to three independent experiments. Error bars represent 
standard error of the mean. B) The above experiment was replicated with three CDK9 
inhibitors: PHA-767491 (2.5 μM), SNS-032 (156 nM) or flavopiridol (125 nM). Data are 
the average of two to four independent experiments. Error bars represent standard error of 
the mean.  
The results of this preliminary investigation support the hypothesis that the sensitizing 
effect of PHA-767491 is due to inhibition of CDK9 and not simply an effect of general 
transcription inhibition. Furthermore, these results establish that targeting promoter escape in 
particular results in greater sensitization than targeting other steps of transcription. This is 
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consistent with the hypothesis that combining the mithramycin blockade of EWS-FLI1-driven 
transcription initiation with blockade of the next step in transcription, i.e., promoter escape, 
results in a synergistic block of EWS-FLI1 activity and Ewing sarcoma cell growth. 
 
Conclusions 
The results of this study definitively establish PHA-767491 and 20 nM mithramycin as a 
promising combination therapy for Ewing sarcoma. This combination clearly inhibits EWS-FLI1 
activity and achieves sustained suppression of Ewing sarcoma cell growth. Furthermore, these 
effects are similar to the effects of a higher concentration of mithramycin known to block 
EWS-FLI1 activity. In addition, this study demonstrates that inhibition of promoter escape via 
CDK9 is an effective method of sensitizing Ewing sarcoma cells to the bioachievable 
concentration of mithramycin. Lastly, it identifies two additional CDK9 inhibitors, flavopiridol 
and SNS-032, as potential mithramycin sensitizers.  
Future directions will include evaluating a panel of CDK9 inhibitors to identify the 
optimal CDK9 inhibitor to potentiate the mithramycin-mediated blockade of EWS-FLI1. The top 
two compounds will then be evaluated in an established mouse xenograft model of Ewing 
sarcoma to ensure that the improvement in the mithramycin-mediated effect is not accompanied 
by a parallel increase in toxicity (79). Using this strategy, we expect to identify a novel 
combination therapy that utilizes mithramycin to achieve clinical suppression of EWS-FLI1 and 
improve Ewing sarcoma patient survival.  
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CHAPTER III 
 
EXPANDING THE THERAPEUTIC WINDOW OF MITHRAMYCIN BY MITIGATING 
LIVER TOXICITY 
 
Introduction 
In a phase I/II clinical trial of mithramycin for Ewing sarcoma patients, two of the five 
enrolled patients with recurrent refractory Ewing sarcoma treated with mithramycin had stable 
disease for more than 40 days. These responses were seen with very few side effects, including 
no significant nausea, vomiting, hair loss, myelosuppression, nephrotoxicity, or cardiotoxicity. 
The only toxicity observed in these patients was liver toxicity. Unfortunately, this toxicity 
necessitated dose reductions that limited maximum patient plasma levels to approximately 
20 nM mithramycin, which likely accounts for the modest activity of this drug in the clinic.  
Mithramycin is a DNA binding compound known to bind-GC rich regions of the genome 
(80). One obstacle that has limited the use of DNA binding compounds in the clinic is their 
propensity to generate non-specific DNA damage in normal tissues, which can lead to patient 
toxicity. Because mithramycin is a DNA binding compound, one might hypothesize that the 
toxicity of mithramycin is due to non-specific DNA damage. However, because the toxicity was 
limited exclusively to the liver, it seems unlikely that mithramycin toxicity is caused by a 
completely non-specific mechanism, such as DNA damage. Therefore, we hypothesized that 
mithramycin liver toxicity is mediated by a mechanism specific to hepatocytes.  
One consequence of the affinity of mithramycin for GC-rich DNA is the ability to block 
transcription-factor binding to promoter regions and perturb gene expression (80,81). Based on 
work in our laboratory, we believe that the mechanism of mithramycin action in Ewing sarcoma 
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is a blockade of EWS-FLI1 binding to chromatin in Ewing sarcoma cells (manuscript in 
preparation). However, this cannot be the mechanism of mithramycin liver toxicity because 
EWS-FLI1 is not expressed in the liver. Consequently, we reasoned that a potential cause of 
mithramycin toxicity is liver-specific changes in gene expression resulting from mithramycin 
blockade of an alternative transcription factor. 
The goal of this study was to characterize mithramycin-mediated changes in gene 
expression that may be responsible for the context-dependent mithramycin toxicity observed in 
the clinic. To accomplish this goal, a quantitative RT-PCR screen of potential liver toxicity genes 
was performed. BTG2 (BTG family, member 2) was then characterized as the potential causative 
gene responsible for the context-dependent liver toxicity of mithramycin. Knockdown of this 
gene was shown to rescue the toxicity induced by the drug in immortalized hepatocytes. Finally, 
preliminary evidence of a possible mechanism of this activity is presented. 
 
Results and Discussion 
 In order to identify possible causative genes responsible for the context-dependent liver 
toxicity, PCR assays were designed to measure expression of 84 published liver toxicity genes 
representing the majority of known liver toxicity genes (111-127). In order to determine the 
effect of drug exposure on the expression of these genes, HepG2 immortalized hepatocytes were 
incubated with 50 nM mithramycin for 6 hours, RNA was collected, and quantitative RT-PCR 
was performed (Figure 10, A). The majority of genes showed no change in expression with drug 
exposure. However, one gene, BTG2, was markedly induced by mithramycin exposure and this 
induction (fold change = 4.4, SEM ± 0.4; P < 0.0001) was subsequently validated (Figure 10, B). 
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Figure 10. Quantitative RT-PCR liver toxicity screen and validation. A) HepG2 cells 
were incubated with 50 nM mithramycin for 6 hours and fold change in expression of 84 
known hepatotoxicity genes was determined using quantitative RT-PCR. Expression was 
normalized to vehicle-incubated cells. B) To validate the results of the screen, HepG2 
cells were again incubated with 50 nM mithramycin (MMA) for 6 hours and the fold 
change in BTG2 expression was determined using quantitative RT-PCR. Expression was 
normalized to cells incubated with cell culture medium (Control). Data are the average of 
six replicates from three independent experiments. Error bars represent standard error of 
the mean. **** = P < 0.0001 
 BTG2 was originally identified as a TP53-inducible, anti-proliferative protein involved in 
the DNA damage cellular response pathway (128). However, more recent studies have identified 
an expanded role of BTG2 that includes directly driving cell death via apoptosis (129-131). 
BTG2 has also been implicated in the toxicity of doxorubicin, a chemotherapeutic structurally 
related to mithramycin, by augmenting accumulation of intracellular reactive oxygen species 
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(ROS), resulting in increased apoptosis (132). These studies suggest that the mithramycin 
induction of BTG2 in hepatocytes would likely be detrimental to cell survival. Therefore, it is 
possible that the induction of BTG2 by mithramycin is responsible for the drug toxicity in the 
liver by one of these mechanisms. Furthermore, blocking the induction or activity of BTG2 may 
have a protective effect on hepatocytes, which would allow for higher plasma levels of the drug 
and make the suppression of EWS-FLI1 by mithramycin achievable in patients. 
 
Figure 11. Blocking BTG2 induction by siRNA silencing. HepG2 cells were incubated 
with either a negative control siRNA (Mock, MMA) or siRNA targeted against BTG2 
(siBTG2, siBTG2 + MMA) for 24 hours. Cells were then incubated with 50 nM 
mithramycin (MMA, siBTG2 + MMA) or fresh cell culture medium (Mock, siBTG2) for 
6 hours and fold change in BTG2 expression was measured by quantitative RT-PCR. 
Changes in gene expression were normalized to Mock. Data are the average of four 
replicates from two independent experiments. Error bars represent standard error of the 
mean. **** = P < 0.0001 
 In order to model this process in vitro, small interfering RNA (siRNA) gene silencing 
was used. HepG2 cells were incubated with siRNA targeted against BTG2 for 24 hours prior to 
6-hour exposure to 50 nM mithramycin, and BTG2 expression was measured by quantitative RT-
PCR (Figure 11). Consistent with prior results, incubation of HepG2 cells with 50 nM 
mithramycin in the presence of a non-targeting control siRNA led to the induction of BTG2 (fold 
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change = 4.2, SEM ± 0.4; P < 0.0001). In addition, siRNA targeting of BTG2 markedly 
suppressed expression (fold change = 0.4, SEM ± 0.1; P < 0.0001), leading to no overall change 
when combined with 50 nM mithramycin (fold change = 1.02, SEM ± 0.05). Therefore, siRNA 
silencing of BTG2 prior to mithramycin exposure blocks induction of BTG2. 
  
Figure 12. Effect of blocking BTG2 induction on HepG2 cell proliferation. Time-
lapse microscopy was used to monitor the proliferation of HepG2 cells as indicated by 
change in percent confluence. Cells were incubated with either a non-targeting siRNA 
(Mock, MMA) or siRNA targeted against BTG2 (siBTG2, siBTG2 + MMA) for 24 
hours. Cells were then incubated with 50 nM mithramycin (MMA, siBTG2 + MMA) or 
fresh cell culture medium (Mock, Media) and cell growth was measured over time by 
time-lapse microscopy. Data are representative of three independent experiments. Error 
bars represent standard error of the mean. 
To demonstrate that blocking induction of BTG2 is protective of hepatocytes, the 
proliferation of HepG2 cells incubated with 50 nM mithramycin with and without prior BTG2 
silencing was monitored by time-lapse microscopy (Figure 12). Cells incubated with fresh cell 
culture medium and cells incubated with a non-targeting control siRNA grew to 70% confluence 
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(SEM ± 8 and ± 10, respectively) by 96 hours. Cells incubated with siRNA silencing of BTG2 
alone grew to 83% confluence (SEM ± 5) by 96 hours, indicating a modest growth advantage 
with BTG2 silencing. Exposure to 50 nM mithramycin alone reduced cell confluence to 39% 
(SEM ± 1) by 96 hours. In contrast, blocking BTG2 induction by silencing BTG2 prior to 
mithramycin exposure increased confluence by 21% and virtually restored the percent 
confluence to the level of control by 96 hours (60% siBTG2, SEM ± 1 vs. 70% control). This 
represented a near doubling of the growth advantage observed with BTG2 silencing alone. 
Therefore, blocking BTG2 induction increases HepG2 cell proliferation, indicative of a 
protective effect on hepatocytes. These effects were confirmed by a second viability assay, the 
MTS assay (Figure 13). In this case, siRNA silencing of BTG2 roughly doubled hepatocyte cell 
survival in cells incubated with 50 nM mithramycin from 22% (SEM ± 1.2) to 54% (SEM ± 1.7; 
P < 0.0001). However, it is notable that the overall toxicity of mithramycin was higher when 
measured in this manner. 
 In order to lend credence to the overall theory, the context dependence of BTG2 
induction was investigated by comparing the change in BTG2 expression in HepG2 cells to 
TC32 Ewing sarcoma cells by quantitative RT-PCR (Figure 14). In contrast to HepG2 cells, 
incubation of TC32 cells with 50 nM mithramycin for 6 hours did not induce BTG2 and actually 
led to a 1.5-fold suppression at the identical concentration and length of exposure (fold 
change = 0.68, SEM ± 0.06; P = 0.006). This disparate change in BTG2 expression between 
HepG2 cells and TC32 cells is consistent with the overall theory that the effect of mithramycin 
on gene expression is context-dependent. Furthermore, it establishes that blocking BTG2 
induction is a reasonable strategy to mitigate liver toxicity because BTG2 induction is clearly not 
involved in the mechanism of mithramycin action against Ewing sarcoma cells. 
32 
 
 
 
Figure 13. Effect of blocking BTG2 induction on HepG2 cell viability. Cells were 
incubated with either a non-targeting siRNA (Mock, MMA) or siRNA targeted against 
BTG2 (siBTG2, siBTG2 + MMA) for 24 hours. Cells were then incubated with 50 nM 
mithramycin (MMA, siBTG2 + MMA) or fresh cell culture medium (siBTG2, Mock) for 
72 hours. Cell viability was measured by the MTS assay and normalized to cells 
incubated with cell culture medium. Data are the average of three independent 
experiments. Error bars represent standard error of the mean. **** = P < 0.0001 
 
 
Figure 14. Effect of mithramycin on BTG2 expression in Ewing sarcoma cells. TC32 
cells were incubated with vehicle control (Control) or 50 nM mithramycin (MMA) for 6 
hours and quantitative RT-PCR was used to determine the fold change in BTG2 
expression. Data are the average of two replicates from two independent experiments. 
Error bars represent standard error of the mean. ** = P = 0.006 
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BTG2 has been shown to enhance cell death by augmenting accumulation of intracellular 
reactive oxygen species (ROS) and has been previously implicated in the toxicity of the 
chemotherapeutic agent doxorubicin (132). This study demonstrated that overexpression of 
BTG2 increased apoptosis in HepG2 cells incubated with doxorubicin. Like mithramycin, 
doxorubicin is a flat planar aromatic compound known to cause liver toxicity (133-135). 
Therefore, it seemed reasonable that the liver toxicity effect of BTG2 induction could be 
mediated by accumulation of intracellular ROS. 
To investigate ROS production in hepatocytes incubated with mithramycin, electron 
paramagnetic resonance (EPR) spectroscopy was used to measure superoxide radical production 
in HepG2 cells (136-138). Superoxide radical was measured because it is one of the three major 
species of ROS and is a precursor to the other two major species of ROS, namely, hydrogen 
peroxide and hydroxyl radical (139,140). Furthermore, overproduction of superoxide has been 
shown to result in oxidative stress leading to cellular dysfunction and cell death (141). Therefore, 
measuring superoxide radical production is a useful indication of intracellular ROS levels and 
potential oxidative stress. 
In this experiment, HepG2 cells were incubated with 20 nM or 50 nM mithramycin for 24 
hours, and superoxide radical levels were measured by EPR spectroscopy (Figure 15). Relative 
to cells incubated with vehicle control, incubation with 20 nM mithramycin resulted in a modest 
increase in superoxide levels from 80 pmol/mg protein (SEM ± 6) to 96 pmol/mg protein 
(SEM ± 10); however, this increase was not statistically significant. In contrast, 50 nM 
mithramycin exposure caused a significant increase in superoxide levels to 119 pmol/mg protein 
(SEM ± 9; P = 0.02). In addition, siRNA silencing of BTG2 expression reduced superoxide 
levels to 52 pmol/mg protein (SEM ± 3; P = 0.02) and rescued superoxide levels close to 
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baseline when combined with 50 nM mithramycin (88 pmol/mg protein, SEM ± 3). Relative to 
50 nM mithramycin alone, this decrease was statistically significant (P = 0.03). 
These data suggest that ROS may play a role in the liver toxicity induced by 50 nM 
mithramycin. It is known that increases in superoxide levels by 20% or more are physiologically 
relevant (Sergey Dikalov, personal communication). These data also suggest that blocking 
induction of BTG2 reduces the production of intracellular ROS. However, additional work will 
be necessary to determine if these increases occur in other models of liver toxicity and, more 
importantly, if these effects can be rescued with free radical scavengers such as N-acetyl 
L-cysteine, polyethylene glycol catalase, and polyethylene glycol superoxide dismutase. 
 
Figure 15. Effect of mithramycin on superoxide production in HepG2 cells. HepG2 
cells were exposed to one of five conditions: vehicle control for 24 hours (Veh), 20 nM 
mithramycin for 24 hours (MMA 20 nM), 50 nM mithramycin for 24 hours (MMA 
50 nM), siRNA silencing of BTG2 for 24 hours followed by fresh cell culture medium 
for 24 hours (siBTG2), or siRNA silencing of BTG2 for 24 hours followed by 50 nM 
mithramycin for 24 hours (siBTG2 + MMA 50 nM). Superoxide levels were then 
measured by EPR spectroscopy and normalized to protein content of the sample. Data are 
the average of three replicates from a single experiment. Error bars represent the standard 
error of the mean. * = P < 0.05 
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Conclusions 
 These studies conclusively establish the context-dependent induction of BTG2 by 50 nM 
mithramycin and that this induction is toxic to HepG2 immortalized hepatocytes. In addition, 
these data show that blocking mithramycin induction of BTG2 by siRNA is protective of HepG2 
cells, increasing both cell viability and proliferation. This suggests that blocking either the 
induction or activity of BTG2 is a reasonable strategy for mitigating mithramycin liver toxicity. 
Furthermore, an analysis of superoxide levels in HepG2 cells suggests that induction of ROS is 
connected to BTG2 expression and may play a role in the liver toxicity of mithramycin. 
Future work will focus on determining the mechanism of BTG2-mediated liver toxicity 
by investigating both the upstream causes and downstream effects of BTG2 induction in 
hepatocytes. Additional studies will be conducted to determine the physiological relevance of 
changes in ROS levels and solidify the connection between BTG2 expression and ROS levels. 
From these studies, we expect to identify a mechanism of mithramycin liver toxicity that can be 
blocked by a protective therapy in order to attain higher concentrations of mithramycin in Ewing 
sarcoma patients.  
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CHAPTER IV 
 
MATERIALS AND METHODS 
 
Cell Lines, Cell Culture and Reagents 
Both TC32 and HepG2 cell lines are patient derived. TC32 Ewing sarcoma cells were the gift of 
Dr. Tim Triche (The Saban Research Hospital, Children's Hospital of Los Angeles, CA). HepG2 
hepatocellular carcinoma cells were obtained from ATCC (Manassas, VA). TC32 cells were 
maintained in RPMI 1640 (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine 
serum (Gemini Bio Products, West Sacramento, CA), 100 U/mL penicillin, and 100 μg/mL 
streptomycin (Invitrogen) and 2 mM L-glutamine (Invitrogen). HepG2 cells were maintained in 
MEM (Invitrogen) and supplemented with 10% fetal bovine serum (Gemini Bio Products), 100 
U/mL penicillin, and 100 μg/mL streptomycin (Invitrogen). Cells were maintained at 37 °C in an 
atmosphere of 5% CO2 at a confluence of 80% or less. Cells lines were confirmed by short 
tandem repeat analysis by DDC Medical (Fairfield, OH). 
 
Compounds 
Mithramycin was purchased from Tocris Bioscience (Bristol, UK) and dissolved at a 
concentration of 0.1 mg/mL in phosphate-buffered saline (PBS). PHA-767491 was the kind gift 
of Dr. Scott Hiebert and was dissolved at a concentration of 5 mM in dimethyl sulfoxide 
(DMSO). SN-38 was purchased from Sigma-Aldrich (St. Louis, MO) and dissolved at a 
concentration of 50 μM in DMSO. Triptolide was purchased from Sigma-Aldrich and dissolved 
at a concentration of 1 mg/mL in DMSO. Velcade was purchased from Selleck Chemicals 
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(Houston, TХ) and dissolved at a concentration of 100 μM in DMSO. Flavopiridol was 
purchased from Sigma-Aldrich and dissolved at a concentration of 1 mM in DMSO. SNS-032 
was purchased from Selleck Chemicals and dissolved at a concentration of 5 mg/mL in DMSO. 
Aliquots of the stock solutions were stored at –20 °C. For all experiments, stock solutions were 
thawed and diluted with cell culture medium immediately prior to use. 
 
Time-Lapse Microscopy 
To measure confluence, phase-contrast HD images of cells were collected every 2 hours using 
the IncuCyte ZOOM system (Essen Bioscience, Ann Arbor, MI). These images were analyzed to 
determine the confluence of the cell culture plate using a proprietary algorithm designed for use 
with the IncuCyte system. To accurately distinguish cells from the background, the IncuCyte 
system is trained using a collection of representative images of the specific cell type. For TC32 
cell experiments, 96-well plates were seeded with 1250 cells per well (drug removal 
experiments) or 5000 cells per well (mithramycin sensitization experiment) and incubated 
overnight. The cell culture medium was then aspirated and replaced with fresh medium 
containing the desired concentration of mithramycin and/or PHA-767491. Plates were then 
placed in an IncuCyte for phase-contrast imaging to measure confluence as a function of time. 
For HepG2 cell experiments, 12-well plates were seeded with 175,000 cells per well and allowed 
to incubate with the desired siRNA for 24 hours (see Small Interfering RNA (siRNA) Silencing 
below). Plates were placed in an IncuCyte at the time of cell seeding for phase-contrast imaging 
to measure confluence as a function of time for the entire length of the experiment. A 
concentrated solution of mithramycin was then added to the appropriate wells to achieve a final 
concentration of 50 nM, and an equivalent volume of cell culture medium was added to control. 
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Quantitative RT-PCR 
For TC32 cell experiments, cells were seeded at a density of either 300,000 cells per well 
(NR0B1 expression experiments) or 400,000 cells per well (BTG2 expression experiments) in a 
6-well dish and incubated over night. The growth medium was removed and replaced with 
freshly diluted mithramycin and/or PHA-767491 at the concentrations indicated in the 
experiment. Freshly diluted vehicle-control medium was added to control. For HepG2 cell 
experiments, cells were seeded at a density of 175,000 in a 12-well dish and allowed to recover 
for 24 hours. Freshly diluted mithramycin was then added to the cell culture medium to a final 
concentration of 50 nM. An equivalent volume of cell culture medium was added to control. For 
both TC32 and HepG2 cell experiments, cells were incubated for either 18 hours (NR0B1 
expression experiments) or 6 hours (BTG2 expression experiments), and RNA was subsequently 
collected using an RNeasy kit (Qiagen, Germantown, MD) according to the manufacturer’s 
instructions. After collection, RNA quantity and quality was assessed using a NanoDrop ND-
1000 spectrophotometer (NanoDrop Products, Wilmington, DE). RNA (1800 ng) was 
subsequently reverse transcribed using 10x RT Buffer, 25x dNTPs and reverse transcriptase from 
a high-capacity reverse transcriptase kit (Applied Biosystems, Norwalk, CT) and Oligo d(T)16 
Primer (Invitrogen) in a Veriti 96-well Thermal Cycler (Applied Biosystems) according to the 
following program: 25 °C for 10 minutes, 37 °C for 60 minutes for two cycles, and 85 °C for 5 
minutes. The resultant cDNA was PCR amplified using reverse and forward primers specific for 
the target gene (see below) mixed with the iTaq Universal SYBR Green Supermix (Bio-Rad) 
using either a CFX96 Real Time System (Bio-Rad) or CFX384 Real Time System (Bio-Rad) 
according to the following program: 95 °C for 10 minutes followed by 95 °C for 30 seconds, 
55 °C for 30 seconds, and 72 °C for 30 seconds for 40 cycles. 
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NR0B1 Forward Primer: CAGTGGGGAACTCAGCAAAT 
NR0B1 Reverse Primer: ATCATCCATGCTGACTGTGC 
BTG2 Forward Primer: ACCACTGGTTTCCCGAAAAG 
BTG2 Reverse Primer: CTGGCTGAGTCCGATCTGG 
GAPDH Forward Primer: GAAGGTGAAGGTCGGAGTC 
GAPDH Reverse Primer: GAAGATGGTGATGGGATTTC 
Expression was determined by comparing the average threshold cycle (Ct) for treated samples to 
the average Ct for control samples and using the Pfaffl equation to determine fold change in gene 
expression (142). To determine the average Ct in the samples, the Ct of NR0B1 or BTG2 was 
normalized to the Ct of the housekeeping gene GAPDH. 
 
Western Blot Analysis 
TC32 cells were plated on 10-cm cell culture dishes at a cell density of 1.5 x 10
6
 and allowed to 
recover overnight. The cell culture medium was removed and replaced with fresh cell culture 
medium containing the concentration of mithramycin and/or PHA-767491 indicated in the 
experiment. Cells were allowed to incubate for 18 hours, scraped into cold PBS, washed twice 
with PBS, and lysed with 4% lithium dodecyl sulfate buffer (Sigma-Aldrich). The protein 
content of the cell lysates was determined using the bicinchoninic acid (BCA) assay (Pierce, 
Rockford, IL) according to the manufacturer’s instructions. Cell lysate samples (30 μg protein 
per sample) were then diluted into NuPAGE LDS Sample Buffer (4X) (Novex, Carlsbad, CA) 
and boiled at 100 °C for 10 minutes. Cell lysate samples were loaded on a NuPAGE 4%–12% 
Bis-Tris Gel (Novex) and resolved via electrophoresis at 115 V for approximately 1.5 hours in 
3-(N-Morpholino)propanesulfonic acid (MOPS) sodium dodecyl sulfate (SDS) buffer (Novex). 
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After sample resolution on the gel, samples were transferred overnight via electrophoresis at 
20 V to nitrocellulose membranes (Whatman, Little Chalfront, UK) using SDS/Glycine Buffer 
(Bio-Rad, Hercules, CA) with 20% methanol (Sigma-Aldrich). The membranes were probed 
with the following antibodies: mouse monoclonal anti-phospho-histone H2A.X (ser 139) 
(γH2AX) (1:2000 dilution; EMD Millipore, Billerica, MA), rabbit monoclonal anti-ID2 (1:1000 
dilution; Cell Signaling, Danvers, MA), mouse monoclonal anti-GAPDH (1:2000 dilution; 
Abcam, Cambridge, UK), rabbit polyclonal anti-NR0B1 (1:1000 dilution; Abcam), rabbit 
polyclonal anti-FL1 (1:1000 dilution; Abcam), and rabbit monoclonal anti-EZH2 (1:5000 
dilution, Cell Signaling). After primary antibody incubation, membranes were incubated with 
horseradish peroxidase (HRP)-conjugated polyclonal anti-mouse or anti-rabbit immunoglobulin 
(IgG) (1:1000 or 1:2000; Promega, Madison, WI) and subsequently visualized using ECL Prime 
Western Blotting Detection Reagent (Amersham, Buckinghamshire, UK). 
 
Cell Viability Assay 
Cell viability of both TC32 and HepG2 cells was determined using the colorimetric CellTiter 96 
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, 
inner salt (MTS) assay (Promega). For TC32 experiments, cells were plated at a density of 5000 
cells per well in a 96-well plate and allowed to recover overnight. The cell culture medium was 
removed and replaced with medium containing the compound(s) indicated in the experiment at 
the desired concentrations. Cells were incubated for 47 hours, 20 μL of CellTiter 96 reagent 
(Promega) was added to each well, and cells were incubated for an additional 1 hour at 37 °C. 
The resulting color change was measured by determining percent transmittance of 490 nM light 
using a VersaMax tunable microplate reader (Molecular Devices, Sunnyvale, CA) and 
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quantitated against a standard curve to determine cell number. The data were subsequently 
normalized to vehicle-incubated control to determine percent viability and the half-maximal 
inhibition of viability value (IC50) of each compound was determined by nonlinear regression 
using Prism 5.0 software (GraphPad Software Inc., La Jolla, CA). For HepG2 experiments, 2500 
cells were seeded per well in a 96-well plate and allowed to incubate with either a negative 
control siRNA, siRNA targeted against BTG2 or cell culture medium for 24 hours (see Small 
Interfering RNA (siRNA) Silencing below). A freshly diluted, concentrated mithramycin 
solution was then added to the appropriate wells to achieve a final concentration of 50 nM. An 
equivalent volume of cell culture medium was added to control. Cells were then incubated for an 
additional 72 hours, after which MTS was added and cell number was quantified as described 
above. The data were then normalized to cells incubated with cell culture medium to determine 
percent viability. 
 
Liver Toxicity Quantitative RT-PCR Screen 
HepG2 cells were seeded in a 6-well plate at a density of 400,000 cells per well and incubated 
over-night. The medium was aspirated and replaced by fresh medium containing either 50 nM 
mithramycin or vehicle control and incubated for 6 hours. RNA was collected using an RNeasy 
kit (Qiagen) and reverse transcribed into cDNA as described above. The resultant cDNA was 
mixed with iTaq Universal SYBR Green Supermix (Bio-Rad) and 10 μL per well (1800 ng 
cDNA per well) were loaded by an epMotion 5070 automated pipetting system (Eppendorf, 
Hamburg, Germany) in a predesigned 384-well plate containing dried primer sets of the Human 
Hepatotoxicity RT
2
 Profiler™ PCR Array (Bio-Rad). The cDNA was then PCR amplified using 
a CFX384 Real Time System (Bio-Rad) according to the following program: 95 °C for 2 minutes 
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followed by 95 °C for 5 seconds and 60 °C for 30 seconds for 40 cycles. Expression was 
determined as described above. To determine the average Ct in samples, the Ct of liver toxicity 
target genes was normalized to the geometric mean of the Ct of the following six housekeeping 
genes: ACTB, B2M, GAPDH, HPRT1, RPLP0 and TBP (143). 
  
Small Interfering RNA (siRNA) Silencing 
A pre-designed siRNA targeting BTG2 was purchased from Ambion (Austin, TX) and used to 
silence BTG2 expression. Allstars Negative Control siRNA and Allstars Hs Cell Death Control 
siRNA were obtained from Qiagen and used as negative and positive controls, respectively, for 
siRNA transfection. All siRNA was obtained as a lyophilized powder and subsequently 
resuspended using RNAse free water to 20 μM stock solutions. Stock solutions were aliquoted 
and stored at –20 °C to limit freeze-thaw cycles. The 20 μM stock solutions were diluted and 
added to cell culture plates as 20 nM working solutions. The siRNA was then incubated with an 
appropriate volume of Lipofectamine RNAiMAX Transfection Reagent (Invitrogen) for 30 
minutes. HepG2 cells intended for RNA collection or time-lapse microscopy were seeded in a 
12-well cell culture plate at a density of 175,000 cells per well. HepG2 cells plated for 
measurement of viability were seeded in a 96-well cell culture plate at a density of 2500 cells per 
well. The cells were incubated for 24 hours to allow for target gene expression silencing. After 
24 hours, an appropriate volume of a concentrated solution of mithramycin was added to the cell 
culture well such that the final concentration of mithramycin was 50 nM. An equivalent volume 
of cell culture medium was added to control. Collection of RNA and subsequent measures of 
gene expression by quantitative RT-PCR were completed as described above. Time-lapse 
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microscopy experiments were completed as described above. Cell viability was measured by the 
MTS assay as described above. 
 
Reactive Oxygen Species Analysis 
For BTG2 silencing, 2.5 x 10
6
 HepG2 cells were seeded on 10-cm cell culture dishes and 
incubated with siRNA targeting BTG2 for 24 hours. Cells were then incubated with either 50 nM 
mithramycin or an equivalent volume of cell culture medium for 24 hours before superoxide 
levels were measured. siRNA suppression of BTG2 was confirmed by quantitative RT-PCR as 
described above. For mithramycin exposure without BTG2 silencing, HepG2 cells were plated 
on 10-cm cell culture dishes at a cell density of 2.5 x 10
6
 and allowed to recover overnight. The 
cell culture medium was aspirated and replaced with freshly diluted vehicle control or 
mithramycin at the concentrations indicated in the experiment. Cells were then incubated for 24 
hours, whereupon superoxide levels were measured. Superoxide levels were determined by 
electron paramagnetic resonance (EPR) spectroscopy in collaboration with Sergey Dikalov of the 
Free Radicals in Medicine CORE at Vanderbilt University as described previously (136). Briefly, 
after mithramycin exposure, cells were incubated with spin probes at 37 °C before collection into 
0.6 mL Krebs-HEPES buffer (pH 7.4). The suspension was subsequently snap-frozen in liquid 
nitrogen and the EPR spectra were recorded. Cellular EPR signal was then calculated by 
subtracting the total EPR signal (measured in absorbance units) from the EPR signal of a blank 
sample. The cellular signal was then normalized to protein content of the sample, which was 
determined by the BCA assay (Pierce) according to the manufacturer’s instructions. 
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Statistical Methods 
Data are presented as mean values with standard error of the mean. The Student t test was 
performed using the Prism 5.0 software (GraphPad Software Inc.) to determine statistical 
significance. All Student’s t tests were unpaired and two-tailed. A P value less than 0.05 was 
considered statistically significant.  
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